Patents Issued in October 17, 2019
  • PROTRANSDUCINE-C: GENE TRANSFER ACTIVATOR
    Publication number: 20190315816
    Abstract: Polypeptide having the sequence
    Type: Application
    Filed: November 8, 2017
    Publication date: October 17, 2019
    Inventors: Wolf-Georg FORSSMANN, Rudolf RICHTER
  • MULTIMERIC AND MULTIVALENT POLYMER COMPRISING MULTIMERIZATION PEPTIDE DOMAIN
    Publication number: 20190315817
    Abstract: A multivalent polymer includes a multimerization peptide domain and a target protein fused directly or indirectly with the multimerization peptide domain. The multivalent polymer exhibits a probe effect by establishing a nano-size by self-assembly, and, accordingly, the multivalent polymer can be advantageously used in the development of a highly sensitive protein nano chip and the development of a diagnostic kit.
    Type: Application
    Filed: June 28, 2019
    Publication date: October 17, 2019
    Inventors: Tae Sung JUNG, Jung Seok LEE, Se Pyeong IM, Jaesung KIM, Young Rim KIM
  • RECOMBINANT POLYPEPTIDES AND METHODS OF USE THEREOF
    Publication number: 20190315818
    Abstract: The present disclosure provides recombinant polypeptides, nucleic acids encoding the recombinant polypeptides and methods for using these polypeptides and/or nucleic acids in enhancing or inducing an immune response in a subject in need thereof. The present disclosure also provides methods of treating a cell proliferative disorder, such as cancer, by administering the disclosed polypeptides and/or nucleic acids to a subject in need thereof.
    Type: Application
    Filed: June 17, 2019
    Publication date: October 17, 2019
    Inventors: YA-Huei CHEN, Ting-long LIN
  • PEPTIDE DIRECTED PROTEIN KNOCKDOWN
    Publication number: 20190315819
    Abstract: In one aspect, the invention provides a peptide comprising a chaperone-mediated autophagy (CMA)-targeting signal domain; a protein-binding domain that selectively binds to a target cytosolic protein; and a cell membrane penetrating domain (CMPD). In another aspect, the invention provides methods for reducing the intracellular expression level of an endogenous target protein in vitro and in an animal, wherein the method involves administration of the peptide. Methods are also provided for treating a pathological condition in an animal, the methods comprising administering the peptide to the animal. In one embodiment, the pathological condition is a neurodegenerative disease. In another embodiment of the invention, the target cytosolic protein is death associated protein kinase 1 and the CMPD is protein transduction domain of the HIV-1 Tat protein.
    Type: Application
    Filed: March 27, 2019
    Publication date: October 17, 2019
    Inventors: Yu Tian Wang, Xuelai Fan, Jack Wuyang Jin
  • A Composition Containing SMAD Protein for Treatment of Autoimmune Diseases, a Fusion Protein Comprising SMAD Protein, an Expression Vector and a Method for Preparing the Same
    Publication number: 20190315820
    Abstract: The present invention relates to a composition and a fusion protein for prevention or treatment of autoimmune diseases, which contain a Smad protein, and provides a method for prevention or treatment of autoimmune diseases, including lupus nephritis and rheumatoid arthritis.
    Type: Application
    Filed: June 17, 2019
    Publication date: October 17, 2019
    Inventors: Sang-Kyou Lee, Sung-Dong Park, Sang Won Lee, Chin Hee Mun
  • COMPOSITIONS COMPRISING HEPCIDIN AND METHODS OF USE THEREOF
    Publication number: 20190315821
    Abstract: Provided herein are improved compositions comprising hepcidin. In some aspects, provided herein are methods of treating a condition with a composition disclosed herein.
    Type: Application
    Filed: February 22, 2019
    Publication date: October 17, 2019
    Inventors: James Rolke, Harry Wang
  • Growth Differentiation Factor 15 (GDF-15) Polypeptides
    Publication number: 20190315822
    Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Application
    Filed: May 17, 2019
    Publication date: October 17, 2019
    Applicant: Amgen Inc.
    Inventors: Yumei XIONG, Yi ZHANG, Jackie Z. SHENG, Agnes Eva HAMBURGER, Murielle M. VENIANT-ELLISON, Grant SHIMAMOTO, Xiaoshan MIN, Zhulun WANG, Jie TANG, Gunasekaran KANNAN, Kenneth W. WALKER, Bryan LEMON
  • SMALL CATIONIC ANTI-BIOFILM AND IDR PEPTIDES
    Publication number: 20190315823
    Abstract: The present invention relates generally to peptides and more specifically to anti-biofilm and immunomodulatory peptides.
    Type: Application
    Filed: April 24, 2019
    Publication date: October 17, 2019
    Applicant: The University of British Columbia
    Inventors: Robert E.W. Hancock, Cesar de la Fuente Nunez, Jason Kindrachuk, Havard Jenssen, Joerg Overhage, Evan Haney
  • MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS
    Publication number: 20190315824
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: June 12, 2019
    Publication date: October 17, 2019
    Applicants: ModernaTX, Inc., ModernaTX, Inc.
    Inventors: Antonin DE FOUGEROLLES, Justin GUILD
  • RNA VIRUSES EXPRESSING IL-12 FOR IMMUNOVIROTHERAPY
    Publication number: 20190315825
    Abstract: The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding an IL-12 polypeptide, wherein said IL-12 polypeptide is an IL-12 fusion polypeptide comprising a p35 subunit of an IL-12 and a p40 subunit of an IL-12; to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer.
    Type: Application
    Filed: June 28, 2019
    Publication date: October 17, 2019
    Applicants: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS UNIVERSITAET
    Inventors: Guy UNGERECHTS, Christine ENGELAND, Ruta VEINALDE
  • Method for Increasing the Secretion Levels of Interleukin 2 and Proteins Derived from it
    Publication number: 20190315826
    Abstract: The present invention relates to the field of Biotechnology, particularly to a method based on the introduction of a single mutation in the genes encoding the human IL-2 and the muteins derived thereof that results in increased secretion levels in different hosts without affecting their biological functions. In particular, these mutations are based on a non-conservative change in the amino acid located in position 35 in the primary sequence of human IL-2, preferably the substitutions are K35E, K35D and K35Q. Another object of the present invention are the expression systems used to obtain both the recombinant human IL-2 and the muteins derived thereof using the method described in this invention. The above-mentioned method is useful to improve the production efficiency of the recombinant human IL-2 and the muteins derived thereof both at laboratory and industrial scales.
    Type: Application
    Filed: November 10, 2017
    Publication date: October 17, 2019
    Inventors: GERTRUDIS ROJAS DORANTES, KALET LEÓN MONZÓN, TANIA CARMENATE PORTILLA
  • COMPOSITIONS AND METHODS FOR TREATMENT OF TYPE 1 DIABETES
    Publication number: 20190315827
    Abstract: The present invention provides compositions and methods for treating insulin-dependent diabetes mellitus in a subject comprising administration of a self-vector encoding and expressing human proinsulin.
    Type: Application
    Filed: November 21, 2018
    Publication date: October 17, 2019
    Applicant: Tolerion, Inc.
    Inventors: Bart O. Roep, William H. Robinson, Paul Utz, Hideki Garren, Lawrence Steinman
  • INSULIN-FC FUSIONS AND METHODS OF USE
    Publication number: 20190315828
    Abstract: The present disclosure relates generally to compositions of insulin-Fc (e.g., proinsulin-Fc) fusion proteins and their use to treat autoimmune disease, e.g., autoimmune diabetes, e.g., Type 1 diabetes.
    Type: Application
    Filed: June 12, 2019
    Publication date: October 17, 2019
    Applicant: Akston Biosciences Corporation
    Inventors: Thomas M. Lancaster, Todd C. Zion, Thillainayagam Sathiyaseelan, Sylaja Murikipudi
  • COMPOSITIONS AND METHODS OF CHIMERIC AUTOANTIBODY RECEPTOR T CELLS
    Publication number: 20190315829
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
    Type: Application
    Filed: April 22, 2019
    Publication date: October 17, 2019
    Inventors: Aimee S. Payne, Christoph T. Ellebrecht, Vijay Bhoj, Michael C. Milone
  • COMPOSITIONS AND METHODS OF CHIMERIC AUTOANTIBODY RECEPTOR T CELLS
    Publication number: 20190315830
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
    Type: Application
    Filed: April 22, 2019
    Publication date: October 17, 2019
    Inventors: Aimee S. PAYNE, Christoph T. ELLEBRECHT, Vijay BHOJ, Michael C. MILONE
  • COMPOSITIONS AND METHODS OF CHIMERIC AUTOANTIBODY RECEPTOR T CELLS
    Publication number: 20190315831
    Abstract: The invention includes compositions comprising at least one chimeric autoantibody receptor (CAAR) specific for an autoantibody, vectors comprising the same, compositions comprising CAAR vectors packaged in viral particles, and recombinant T cells comprising the CAAR. The invention also includes methods of making a genetically modified T cell expressing a CAAR (CAART) wherein the expressed CAAR comprises a desmoglein extracellular domain.
    Type: Application
    Filed: April 22, 2019
    Publication date: October 17, 2019
    Inventors: Aimee S. PAYNE, Christoph T. ELLEBRECHT, Vijay BHOJ, Michael C. MILONE
  • NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS
    Publication number: 20190315832
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: May 15, 2019
    Publication date: October 17, 2019
    Inventors: Andrea MAHR, Toni WEINSCHENK, Colette SONG, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
  • Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer and other cancers
    Publication number: 20190315833
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: May 28, 2019
    Publication date: October 17, 2019
    Inventors: Andrea MAHR, Toni WEINSCHENK, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
  • SIRP alpha-CD70 FUSION PROTEIN AND METHODS OF USE THEREOF
    Publication number: 20190315834
    Abstract: SIRPalpha-CD70 fusion proteins are provided. Accordingly, there is provided a SIRPalpha-CD70 fusion protein comprising a single amino acid linker between the SIRPalpha and the CD70. Also there is provided a SIRPalpha-CD70 fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRPalpha-CD70 fusion protein, host-cells expressing the SIRPalpha-CD70 fusion protein and methods of use thereof.
    Type: Application
    Filed: January 4, 2018
    Publication date: October 17, 2019
    Inventors: Noam SHANI, Yosi GOZLAN, Michal DRANITZKI ELHALEL, Edwin BREMER, Ido KAMINSKY
  • FACTOR VIII COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20190315835
    Abstract: The present invention relates to compositions comprising factor VIII coagulation factors linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of factor VIII-related diseases, disorders, and conditions.
    Type: Application
    Filed: March 29, 2019
    Publication date: October 17, 2019
    Inventors: Volker SCHELLENBERGER, Pei-Yun CHANG, Fatbardha VARFAJ, John KULMAN, Tongyao LIU, Garabet G. TOBY, Haiyan JIANG, Robert PETERS, Deping WANG, Baisong MEI, Joshua SILVERMAN, Chia-Wei WANG, Benjamin SPINK, Nathan GEETHING
  • ALBUMIN VARIANTS
    Publication number: 20190315836
    Abstract: The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: May 6, 2019
    Publication date: October 17, 2019
    Inventor: Karen Ann Delahay
  • P97 FUSION PROTEINS
    Publication number: 20190315837
    Abstract: Provided are p97 (melanotransferrin)-trastuzumab fusion proteins and related methods of use thereof, for instance, to facilitate delivery of trastuzumab across the blood-brain barrier (BBB) and/or improve tissue penetration of the antibody in CNS and peripheral tissues, and thereby treat and/or diagnose HER2-positive cancers, including those of the central nervous system (CNS).
    Type: Application
    Filed: February 10, 2019
    Publication date: October 17, 2019
    Inventors: Timothy Z. Vitalis, Reinhard Gabathuler
  • ANTIBODIES THAT BIND ZIKA VIRUS ENVELOPE PROTEIN AND USES THEREOF
    Publication number: 20190315838
    Abstract: Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: October 13, 2017
    Publication date: October 17, 2019
    Inventors: Ram SASISEKHARAN, Kannan THARAKARAMAN, Kuan Rong CHAN, Satoru WATANABE, Subhash G. VASUDEVAN, Eng Eong OOI
  • DENGUE VIRUS-LIKE PARTICLE, ANTIBODY AGAINST DENGUE VIRUS, AND COMPOSITION COMPRISING THE SAME
    Publication number: 20190315839
    Abstract: The present invention is related to a Dengue virus-like particle. Said Dengue virus-like particle exhibits almost-cut pr-M junction and is particularly suitable for producing antibody that recognizes all four types of Dengue virus. The present invention also provides antibody obtained by using said virus-like particle and composition comprising the same.
    Type: Application
    Filed: October 26, 2017
    Publication date: October 17, 2019
    Inventor: Day-Yu CHAO
  • ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND METHODS OF USE
    Publication number: 20190315840
    Abstract: The disclosure provides anti-DENV antibodies and methods of making and using the same. Nucleic acids encoding anti-DENV antibodies and host cells comprising the nucleic acids are also provided. The anti-DENV antibodies have uses that include treating DENV infection. The disclosure also provided polypeptides containing a variant Fc region and methods of making the same. Nucleic acids encoding polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include treating a viral infection. Also claimed is a polypeptide comprising a Fc variant comprising at least one amino acid alteration in Sa parent Fc region, wherein the variant Fc region has a substantially decreased FcYR-binding activity and does not have a substantially decreased C1q-binding activity when compared to the parent Fc region.
    Type: Application
    Filed: June 10, 2019
    Publication date: October 17, 2019
    Inventors: Zenjiro SAMPEI, Xing'er Christine KOO, Katja FINK, Roland ZUEST
  • Antibody-Based Molecules Specific for the Truncated ASP421 Epitope of Tau and Their Uses in the Diagnosis and Treatment of Tauopathy
    Publication number: 20190315841
    Abstract: The present invention relates to antibody-based molecules (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to the truncated Asp421 epitope of Tau. Such antibody-based molecules are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis and/or treatment of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The antibody-based molecules of the present invention have particular utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.
    Type: Application
    Filed: August 11, 2016
    Publication date: October 17, 2019
    Applicant: New York University
    Inventor: Einar Sigurdsson
  • INHIBITORS OF COMPLEMENT FACTOR H
    Publication number: 20190315842
    Abstract: Disclosed herein are Complement factor H (CFH) inhibitors, such as anti-CFH antibodies and small molecules, and methods of using said inhibitors.
    Type: Application
    Filed: November 20, 2018
    Publication date: October 17, 2019
    Inventors: Edward F. Patz, Jr., Michael J. Campa, Elizabeth Gottlin, Barton F. Haynes, Hua-Xin Liao, M. Anthony Moody
  • ANTIBODIES RECOGNIZING ALPHA-SYNUCLEIN
    Publication number: 20190315843
    Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
    Type: Application
    Filed: April 16, 2019
    Publication date: October 17, 2019
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
  • ANTI-GP73 MONOCLONAL ANTIBODIES AND METHODS OF OBTAINING THE SAME
    Publication number: 20190315844
    Abstract: Disclosed herein are antibodies and methods of using said antibodies to detect Golgi protein 73 (GP73) and fucosylated GP73 in a sample.
    Type: Application
    Filed: April 17, 2019
    Publication date: October 17, 2019
    Inventors: Bailin Tu, Robert N. Ziemann, Bryan C. Tieman, Philip M. Hemken, Carol S. Ramsay, Carolyn J. Strobel, David J. Hawksworth, Larry G. Birkenmeyer, Cheng Zhao, Susan E. Brophy, Barry L. Dowell, Anthony S. Muerhoff
  • HUMANIZED ANTI-COMPLEMENT FACTOR C1Q ANTIBODIES AND USES THEREOF
    Publication number: 20190315845
    Abstract: The present disclosure is directed to humanized anti-C1q antibodies and methods of using them.
    Type: Application
    Filed: May 17, 2019
    Publication date: October 17, 2019
    Inventors: Arnon Rosenthal, Michael Leviten
  • Antibodies to Human Alpha-Synuclein
    Publication number: 20190315846
    Abstract: Described a monoclonal antibody to human alpha-synuclein, and the use of that antibody in treating Parkinson's disease.
    Type: Application
    Filed: December 7, 2017
    Publication date: October 17, 2019
    Applicant: THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH
    Inventors: Terina N. Martinez, Kuldip Dave, Sonal Das
  • THERAPEUTIC COMBINATIONS USING IGF1R PATHWAY INHIBITORS, AND METHODS TO PREDICT ANTI-IGF1R THERAPEUTIC EFFICACY
    Publication number: 20190315847
    Abstract: Disclosed herein are methods of treating a subject with an estrogen receptor-positive (ER+) breast cancer comprising obtaining a sample of the breast cancer from the subject; determining a level of E-cadherin in the sample is reduced compared to a control; and administering a therapeutically effective amount of an IGF1R pathway inhibitor and an endocrine therapeutic. Also disclosed herein are methods to treat a cancer in a subject comprising administering a therapeutically effective amount of an IGF1R pathway inhibitor and an E-cadherin inhibitor. Also disclosed are methods to predict the likelihood a subject with a breast cancer will respond therapeutically to a treatment comprising administering an IGF1R pathway inhibitor, the method comprising obtaining a sample of the cancer from the subject; and determining a level of E-cadherin in the sample.
    Type: Application
    Filed: February 26, 2019
    Publication date: October 17, 2019
    Inventors: Adrian Lee, Alison Nagle, Steffi Oesterreich
  • ANTI-SECRETOGRANIN III (SCG3) ANTIBODIES AND USES THEREOF
    Publication number: 20190315848
    Abstract: Antibodies specific for secretogranin III (Scg3) are disclosed. Methods of using the antibodies, antigen-bin ding fragments thereof, or pharmaceutical compositions comprising the same in the treatment of diseases such as diabetic retinopathy, neovascular age-related macular degeneration, retinopathy of prematurity, and cancer, are also disclosed.
    Type: Application
    Filed: November 6, 2017
    Publication date: October 17, 2019
    Inventors: Wei Li, Michelle E. Leblanc, Weiwen Wang, Philip J. Rosenfeld
  • METHOD OF TREATING OR PREVENTING STROKE
    Publication number: 20190315849
    Abstract: A method of reducing an effect of stroke in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signaling.
    Type: Application
    Filed: May 14, 2019
    Publication date: October 17, 2019
    Applicants: CSL Limited, B-Creative Sweden AB
    Inventors: Ulf ERIKSSON, Ingrid NILSSON, Daniel LAWRENCE, Enming Joe SU
  • Antibodies Specific for TGF-Beta
    Publication number: 20190315850
    Abstract: The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGF?), including TGF?1, TGF?2 and TGF?3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGF? expression.
    Type: Application
    Filed: June 7, 2019
    Publication date: October 17, 2019
    Inventors: Daniel H. Bedinger, Shireen S. Khan, Amer Mirza, Ajay J. Narasimha, Toshihiko Takeuchi
  • ANTI-ANGPTL3 ANTIBODIES AND USES THEREOF
    Publication number: 20190315851
    Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.
    Type: Application
    Filed: June 7, 2019
    Publication date: October 17, 2019
    Inventors: Mark W. SLEEMAN, Viktoria GUSAROVA, Andrew J. MURPHY
  • COMBINED TREATMENT WITH NETRIN-1 INTERFERING DRUG AND IMMUNE CHECKPOINT INHIBITORS DRUGS
    Publication number: 20190315852
    Abstract: The invention is the combination or combined use of (i) a compound able to disrupt or impede netrin-1/netrin-1 receptors interaction or netrin-1-mediated receptor dimerization, also called herein a NTN1 neutralizing agent, which compound may be an antibody binding to netrin-1 or anti-netrin-1 antibody, and (ii) an immune checkpoint inhibitor, in the treatment of cancer. The composition may comprise an anti-netrin-1 antibody and an immune checkpoint inhibitor, for use as an anticancerous drug with a simultaneous, separate or sequential administration of the anti-netrin-1 antibody and the immune checkpoint inhibitor to a patient.
    Type: Application
    Filed: January 5, 2018
    Publication date: October 17, 2019
    Inventors: Benjamin DUCAROUGE, David GOLDSCHNEIDER, Anna Maria Rita REDAVID, Benjamin GIBERT, Patrick MEHLEN
  • ANTIBODIES TO IL-15
    Publication number: 20190315853
    Abstract: The present invention relates to antibodies binding IL-15, in particular humanized antibodies. In particular, the anti-IL-15 antibodies according to the invention are able to neutralize IL-15 activity and are useful in the prevention and/or treatment of an autoimmune disease and/or inflammatory disorder, a malignancy, transplant rejection, metabolic condition and/or an infectious disease caused by parasitic, viral or bacterial pathogens.
    Type: Application
    Filed: May 24, 2019
    Publication date: October 17, 2019
    Inventors: ALAIN VICARI, OLIVIER LEGER
  • ANTIBODIES, COMPOSITION AND KITS COMPRISING SAME, AND METHODS OF USE THEREOF
    Publication number: 20190315854
    Abstract: Provided are novel antibodies with high target affinities against an IL6 receptor. Further provided are compositions containing such antibodies and methods of using the same.
    Type: Application
    Filed: November 26, 2018
    Publication date: October 17, 2019
    Inventor: Ziqiang Li
  • Therapeutic DLL4 Binding Proteins
    Publication number: 20190315855
    Abstract: DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis.
    Type: Application
    Filed: April 28, 2017
    Publication date: October 17, 2019
    Applicant: AbbVie Inc.
    Inventors: Ming-Jiu Chen, Chung-Ming Hsieh, Jije Gu, Susan Morgan-Lappe, Yingchun Li
  • Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor
    Publication number: 20190315856
    Abstract: The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.
    Type: Application
    Filed: January 25, 2019
    Publication date: October 17, 2019
    Inventors: Anke Kretz-Rommel, Lei Shi, Roger Ferrini, Teddy Yang, Fei Xu, Brian Campion
  • TREATMENT OF PERIPHERAL T CELL LYMPHOMA
    Publication number: 20190315857
    Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.
    Type: Application
    Filed: June 25, 2019
    Publication date: October 17, 2019
    Inventors: CÉCILE BONNAFOUS, HÉLÈNE SICARD, RENAUD BUFFET, MATHIEU BLERY
  • ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20190315858
    Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.
    Type: Application
    Filed: April 11, 2019
    Publication date: October 17, 2019
    Applicant: ALECTOR LLC
    Inventors: Kate Monroe, Tina Schwabe, Francesca Avogadri-Connors, Ilaria Tassi, Helen Lam, Arnon Rosenthal
  • ANTIBODY AGENTS SPECIFIC FOR HUMAN CD19 AND USES THEREOF
    Publication number: 20190315859
    Abstract: Described herein are human antibody agents and multi-specific binding agents that specifically bind human CD 19, in particular, native human CD 19. Also provided herein are methods of using the same or compositions thereof for the detection, prevention and/or therapeutic treatment of diseases characterized by CD 19 expression, in particular, B cell lymphomas and leukemias.
    Type: Application
    Filed: April 18, 2019
    Publication date: October 17, 2019
    Inventors: HONG LIU, Jingwei Lu, Zhiyuan Yang, Li Long, Neal Cheng
  • HUMANIZED AND AFFINITY MATURED ANTIBODIES TO FcRH5 AND METHODS OF USE
    Publication number: 20190315860
    Abstract: The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.
    Type: Application
    Filed: April 25, 2019
    Publication date: October 17, 2019
    Inventors: Isidro HOTZEL, Teemu T. JUNTTILA, Ji LI, Justin SCHEER, Danielle DICARA, Diego ELLERMAN, Christoph SPIESS, Paul J. CARTER
  • METHODS AND COMPOSITIONS FOR INHIBITING CD32B EXPRESSING CELLS
    Publication number: 20190315861
    Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.
    Type: Application
    Filed: May 21, 2019
    Publication date: October 17, 2019
    Applicant: XENCOR, INC.
    Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE PROPHYLACTIC TREATMENT OF METASTASES
    Publication number: 20190315862
    Abstract: The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of metastases. The inventors showed in vivo that lung metastasis in GPVI deficient mice are reduced compared to controls. They demonstrated that GPVI is involved in platetet interaction with tumor cells and this interaction is mediated by EMMPRIN.). Using an anti-EMMPRIN antibody, they showed that the adhesion of platelets to tumors cells is decreased. In particular, the present invention relates to a method for the prophylactic treatment of metastases in a patient suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent which inhibits the interaction between GPVI and EMMPRIN.
    Type: Application
    Filed: November 21, 2017
    Publication date: October 17, 2019
    Inventors: Pierre MANGIN, Christian GACHET
  • TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF
    Publication number: 20190315863
    Abstract: Methods, compositions and uses are provided for bispecific antibodies comprising one or more unnatural amino acids. The bispecific antibodies may bind to two or more different receptors, co-receptors, antigens, or cell markers on one or more cells. The bispecific antibodies may be used to treat a disease or condition (e.g., cancer, autoimmune disease, pathogenic infection, inflammatory disease). The bispecific antibodies may be used to modulate (e.g., stimulate or suppress) an immune response.
    Type: Application
    Filed: May 22, 2019
    Publication date: October 17, 2019
    Inventors: Chanhyuk KIM, Jun Y. AXUP, Hwayoung YUN, Peter G. SCHULTZ, Jennifer MA, Jiayin SHEN, Pengyu YANG
  • SINGLE DOMAIN ANTIBODY AND DERIVATIVE PROTEINS THEREOF AGAINST CTLA4
    Publication number: 20190315864
    Abstract: The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against CTLA4. In particular, the present invention discloses a CTLA4 binding protein and the use thereof, especially the use for treating and/or preventing CTLA4 relevant diseases such as tumor.
    Type: Application
    Filed: May 19, 2017
    Publication date: October 17, 2019
    Inventors: Ting Xu, Xiaoxiao Wang, Jie Li, Haiyan Wu, Li Gao, Qian Chu, Yu Bai
  • METHODS OF TREATING UROTHELIAL CARCINOMA USING AN ANTI-PD-1 ANTIBODY
    Publication number: 20190315865
    Abstract: This disclosure provides a method for treating a subject afflicted with a urothelial carcinoma or cancer derived therefrom, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or the combination of (a) an antibody or an antigen-binding portion thereof that specifically binds to a PD-1 receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.
    Type: Application
    Filed: October 27, 2017
    Publication date: October 17, 2019
    Applicant: Bristol-Myers Squibb Company
    Inventor: Marina TSCHAIKA